Wayne Hogan

Practice Areas: Defective Drugs

Opioid Distributor’s Attorney States: No Obligation to the Public

Big Pharma is facing 2,000 lawsuits from state, local and tribal governments for its role in fueling America’s opioid epidemic which claimed nearly 48,000 lives in 2017 alone. According to an Associated Press story, an attorney for Cardinal Health, one of the country’s largest drug distribution companies, stated under questioning that  “the business has no obligation […]

Read More

Opioid Drug Maker Settles for $270 Million

Purdue Pharma, the maker of Oxycontin, and the Sackler family, founder and owner of Purdue Pharma, have agreed to settle a lawsuit brought by the Oklahoma attorney general for $270 million. OxyContin is an opioid painkiller that was falsely marketed as safe and less addictive. States across the nation are fighting an opioid epidemic that […]

Read More

Opioid Marketing Linked to Opioid Deaths

Nearly 48,000 people died from opioid overdoses in 2017 alone. That accounts for approximately 68% of all deaths due to overdose. A new study published in the JAMA Network Open directly links opioid marketing to the potential increase in prescription opioid deaths. The more money that was spent to market opioids to doctors, the more […]

Read More

We Are All Working for You!

Our firm recently celebrated Wayne Hogan receiving the American Association for Justice 2017 Lifetime Achievement Award. Our firm is like family and what matters at Terrell Hogan is that everyone here shares a passion for the mission to represent our clients as they seek justice. At Terrell, Hogan we’re surrounded by many of the brightest […]

Read More

FDA Warning Regarding Type2 Diabetes Drug Invokana

Two clinical trials of Type2 diabetics taking Johnson & Johnson’s diabetes drug, Invokana, also known also as canagliflozin, have revealed that users are twice as likely to suffer foot and leg amputations than those given a placebo. The U.S. Food and Drug Administration is requiring Johnson & Johnson to add new warnings about the risk […]

Read More

Generic Drugs: Possibly a Worse Deal than We Thought

As we have reported in previous articles, the U.S. Supreme Court’s 2011 ruling in Pliva v. Mensing left patients taking generic drugs with virtually no remedies when they are harmed or killed by defectively designed generic drugs.  The irony of the ruling was that in 2008 the Supreme Court ruled in Wyeth v. Levine that […]

Read More

Heart Attack and Stroke Risk of Non-Steroidal Anti-Inflammatory Drugs

The Food and Drug Administration has issued new, stronger warnings about the risk of heart attack and stroke from over-the-counter nonsteroidal anti-inflammatory drugs “NSAIDs,” including pain relievers ibuprofen and naproxen. The over-the-counter painkillers included in the FDA’s new warning include Aleve (naproxen), Motrin or Advil (ibuprofen) which are normally used to treat things like pain, […]

Read More

Deadline Approaching for Consumer Comments on FDA’s New Generic Drug Label Rule

Consumers have until April 27, 2015 to comment on a new rule for generic drug label changes proposed by the United States Food and Drug Administration (FDA). The proposed rule would address the arbitrary inequality created four years ago by the U.S. Supreme Court’s decision in Pliva v. Mensing, a case in which the court […]

Read More

Are Generic Drugs Always as Good as Name Brands?

In the U.S., generic drugs dominate our medicine cabinets. Indeed, 80% all prescriptions written are filled with generic versions of the brand name drugs prescribed, which saves Americans more than $200 billion annually. But there are no guaranties that generics are as safe or effective as their name brand counterparts. By law, generics are required […]

Read More

FDA Recommends Discontinuing GenStrip Blood Glucose Test Strips Use

The FDA has advised people with diabetes and health care professionals to stop using GenStrip Blood Glucose Test Strips because the strips may report incorrect blood glucose levels. The FDA’s recent inspection found many violations of federal regulations intended to assure quality in the manufacturing of GenStrip Test Strips. The failure to have an adequate […]

Read More